Skip to main content

FSB Sees Some Progress in OTC Reform

mark-carney-financial-stability-board
Mark Carney, FSB

Progress has been made in setting and implementing international standards for over-the-counter (OTC) derivatives market reforms in a number of jurisdictions, according to the latest progress report by the Financial Stability Board (FSB).

Published every six months, the FSB report reviews progress made by international standard-setting bodies, national and regional authorities, and market participants toward getting all standardized OTC contracts to be traded on exchanges or electronic trading platforms and cleared through central counterparties (CCPs), having OTC derivative contracts be reported to trade repositories, and making non-centrally cleared contracts be subject to higher capital requirements.

The jurisdictions with the largest markets in OTC derivatives—the EU, Japan and the US—are the most advanced in structuring their legislative and regulatory frameworks, the report says. They expect to have regulatory frameworks in place by the end of 2012 and practical implementation within their markets is well under way. Other jurisdictions are generally less advanced. One reason is that some jurisdictions have been waiting for the key elements of the regulatory frameworks in the EU, Japan and the US to be finalized before putting their own legislation in place. Others have sought greater certainty about the application of international principles and safeguards to cross-border financial market infrastructure.

Based on its findings, the FSB recommends that market participants expand the number and scope of OTC derivatives transactions that are standardized, centrally cleared, traded on organized platforms and reported to trade repositories.

In the next progress report, to be published before the November G20 Finance Ministers and Central Bank Governors meeting, the FSB intends to put additional focus on the readiness of infrastructures to provide central clearing, platform trading and reporting of OTC derivatives, the practical ability of industry to meet the requirements, and the remaining steps for industry to take.

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@waterstechnology.com or view our subscription options here: https://subscriptions.waterstechnology.com/subscribe

You are currently unable to copy this content. Please contact info@waterstechnology.com to find out more.

Doing a deal? Prioritize info security early

Engaging information security teams early in licensing deals can deliver better results and catch potential issues. Neglecting them can cause delays and disruption, writes Devexperts’ Heetesh Rawal in this op-ed.

Europe is counting its vendors—and souring on US tech

Under DORA, every financial company with business in the EU must report use of their critical vendors. Deadlines vary, but the message doesn’t: The EU is taking stock of technology dependencies, especially upon US providers.

Most read articles loading...

You need to sign in to use this feature. If you don’t have a WatersTechnology account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here